## Article: 0615

Topic: EPW02 - e-Poster Walk Session 02: Consultation Liaison Psychiatry and Psychosomatics, Oncology and Psychiatry, Pain and Treatment Options

Impact of Anti-hypertensive Medication On Psychological Status and Quality of Life in Essential Hypertension

E. Dragioti<sup>1</sup>, D. Tsartsalis<sup>2</sup>, K. Kontoangelos<sup>3</sup>, M. Gouva<sup>1</sup>, P. Sakkas<sup>3</sup>, C. Papageorgiou<sup>3</sup>, I. Kallikazaros<sup>2</sup>

<sup>1</sup>Research Laboratory Psychology of Patients Families and Health Professionals, Higher Technological Educational

Institution of Epirus, Ioannina, Greece ; <sup>2</sup>Department of Cardiology, Hippokration Hospital, Athens, Greece ; <sup>3</sup>First

Department of Psychiatry, Eginition Hospital School of Medicine University of Athens, Athens, Greece

**Background:** Previous findings regarding a possible association among anti-hypertensive medication and dimensions of depressive symptoms, psychopathology and quality of life are mixed.

**Objectives:** This study examined whether anti-hypertensive medication impacts on depressive symptoms, psychopathology and quality of life in a sample of hypertensive patients.

**Aims:** Using a prospective design we aimed to explore the psychological status of hypertensive patients both at baseline and one year later.

**Methods:** A sample of 198 patients (89 men – 108 women, mean age 52, 9 years, SD = 11, 81 ranged 25-78) with a newly diagnosis of essential hypertension was recruited from a general hospital. The questionnaires included at baseline (T1): a) question for the recording of social-demographic characteristics and clinical features, b) The Short Form 36 (SF-36) General Health Survey questionnaire, c) the Beck Depression Inventory –II (BDI-II), and d) The Symptom Checklist-90-Revised (SCL-90-R). Sixty-two participants completed the SF-36, BDI-II and SCL-90-R again one year later (T2).

**Results:** Paired t tests showed that there were not significant differences on the psychological measures from baseline to one-year follow-up (Table 1).

Conclusions: Our findings do not support that anti-hypertensive medication has any impact on depression, general psychopathology and quality of life scores than those who use only a dietary program. Table 1. Descriptive statistics for the psychological variables

	Paired Differences (N=Ω)						
	Mean	SD	95% Confidence Interval of the Difference		t	df	P value
			Lower	Upper	al La constante		
Physical Functioning T1 - T2	.25484	22.62	-5.49128	6.00095	.089	61	.930
Role-Physical (RP) T1-T2	-2.01613	53.99	-15.72945	11.69719	- 294	61	.770
Role-Emotional (RE) T1-T2	-1.61258	41.12	-12.05679	8.83163	309	61	.759
Visiting T1-T2	13689	21.53	-5.65215	5.37838	050	60	.961
Mental Health (MH) T1-T2	2.58065	28.66	-4.69836	9.85965	_709	61	.481
Social Functioning T1-T2	5.24194	34.51	-3.52341	14.00728	1.196	61	.236
Bodily Pain T1-T2	1.37097	30.12	-6.27849	9.02042	.358	61	.721
General Health (GH) T1-T2	92758	24.03	-7.03017	5.17501	304	61	.762
Physical Component Summary (PCS) T1-T2	32903	25.37	-6.77322	6.11516	102	61	.919
Mental Component Summary (MCS) T1-T2	1.48855	23.91	-4.58548	7.56258	.490	61	.626
Som atization T1-T2	033	11.15	-2.896	2.831	023	60	.982
Observive-computive T1-T2	557	9.04	-2.874	1.759	481	60	.632
Interpersonal sensitivity T1-T2	:016	7.21	-1.833	1.865	.018	60	.986
Depression (SCL-90) T1-T2	.770	11.57	-2.195	3.736	.520	60	.605
AnxietyT1-T2	.770	8.45	-1.395	2.936	.712	60	.479
HostilityT1-T2	1.180	5.32	183	2.543	1.732	60	.085
Phobic an aiety T1-T2	902	3.57	-1.816	1.013	-1.972	60	.055
Paranoid id eation T1-T2	.672	6.95	-1.105	2.453	.755	60	.453
Psychoticism T1-T2	052	6.66	-1.789	1.625	096	60	.924
Depressive symptoms (BDI) T1-T2	-1.190	11.13	-3.995	1.614	849	62	.399